Introduction
Aplastic anemia (AA) is a rare and life-threatening heterogeneous bone marrow (BM) failure disorder characterized by peripheral pancytopenia and marrow hypoplasia. 1, 2 The majority of AA cases are idiopathic with an unknown primary etiology. [1] [2] [3] In some patients, a drug or infection is implicated in the etiology of AA although it is unclear why only some individuals are susceptible. [4] [5] [6] [7] In ~15% of patients the disease is inherited or congenital, for example Fanconi anemia. 1, 3 The main suggested underlying mechanism in AA is a primary hematopoietic stem cell (HSC) deficiency or a secondary HSC defect due to an abnormal balance between HSC death and differentiation. 3, 8 Importantly, pathological autoimmune responses also seem to be involved in AA BM failure, given the good responses to immunosuppressive treatments. 1, 9 Mesenchymal stem/stromal cells (MSC) are rare BM multipotent cells that constitute a source of progenitors for mesodermal tissues. 10 MSC have emerged as excellent candidates for clinical applications thanks to their immunomodulatory properties and their ability to support hematopoiesis. [11] [12] [13] Importantly, MSC are an essential component of the BM hematopoietic microenvironment. The BM hematopoietic microenvironment regulates the homeostasis of hematopoiesis through the production and secretion of cytokines and extracellular matrix molecules.
14 Furthermore, the BM hematopoietic microenvironment plays a role in the pathogenesis of a variety of hematologic malignances including acute lymphoblastic 15 and myeloblastic leukemias, 16 multiple myeloma, 17 lymphomas, 18 chronic myeloid leukemia 19 and myelodysplastic syndromes. 16, 20 Because HSC failure and impaired immune responses underlie the pathogenesis of AA, it is plausible that BM-MSC may also contribute, directly or indirectly, to the pathogenesis of AA. However, there is almost no information on whether the functional and immunological properties of BM-MSC are impaired in AA patients or on the potential contribution of Aplastic anemia is a life-threatening bone marrow failure disorder characterized by peripheral pancytopenia and marrow hypoplasia. The majority of cases of aplastic anemia remain idiopathic, although hematopoietic stem cell deficiency and impaired immune responses are hallmarks underlying the bone marrow failure in this condition. Mesenchymal stem/stromal cells constitute an essential component of the bone marrow hematopoietic microenvironment because of their immunomodulatory properties and their ability to support hematopoiesis, and they have been involved in the pathogenesis of several hematologic malignancies. We investigated whether bone marrow mesenchymal stem cells contribute, directly or indirectly, to the pathogenesis of aplastic anemia. We found that mesenchymal stem cell cultures can be established from the bone marrow of aplastic anemia patients and display the same phenotype and differentiation potential as their counterparts from normal bone marrow. Mesenchymal stem cells from aplastic anemia patients support the in vitro homeostasis and the in vivo repopulating function of CD34 + cells, and maintain their immunosuppressive and anti-inflammatory properties. These data demonstrate that bone marrow mesenchymal stem cells from patients with aplastic anemia do not have impaired functional and immunological properties, suggesting that they do not contribute to the pathogenesis of the disease.
Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease 
Methods

Patients
BM samples from nine newly diagnosed AA patients were studied. The diagnosis of AA was based on the UK treatment guidelines. 1 Seven normal BM samples were obtained from healthy volunteers and used as controls. Table 1 
Characterization of mesenchymal stem/stromal cell cultures
The flow cytometry immunophenotype and osteogenic and adipogenic differentiation of BM-MSC was analyzed as previously described.
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Cord blood collection and CD34 + cell isolation
Cord blood (CB) units from healthy neonates were obtained from local hospitals following approval from our local Ethics Board Committee. Mononuclear cells were isolated using FicollHypaque and CD34 + cells purified using the CD34 MicroBead kit and the AutoMACSPro. The purity was consistently >95%. [25] [26] [27] Co-culture of bone marrow mesenchymal stem/stromal cells and cord blood CD34 + cells and in vitro analyses of CD34 + cell homeostasis CD34 + cells were co-cultured on irradiated BM-MSC from normal subjects or patients with AA on serum-free media supplemented with stem cell factor, FLT3 ligand and interleukin-3. In vitro analyses were performed with CD34 + cells without MSC co-culture, as a baseline control for CD34-MSC co-cultures. Growth kinetics, CD34 phenotype, apoptosis, cell cycle analysis and clonogenic progenitor assays were performed, as detailed. 26, 28, 29 Mice xenotransplantation and analysis of engraftment NOD/LtSz-scidIL2Rγ −/− mice (NSG) were housed under sterile conditions. The Animal Care Committee of our University approved animal protocols. Mice at 8-12 weeks of age were sublethally irradiated before intra-BM transplantation. 26, 30 CD34 + cells (1x10 5 ) that had been cultured on normal or AA BM-MSC were transplanted. CD34 + cells not cultured with MSC were transplanted as a control for CD34-MSC co-cultures. Mice were killed 7 weeks after transplantation and human chimerism was analyzed by flow cytometry in the injected and contralateral tibiae, spleen, liver and peripheral blood. 
Determination of anti-inflammatory activity
Synovial membrane cells were obtained from patients with rheumatoid arthritis. These cells ( 2x10 5 ) were stimulated with tumor necrosis factor-α (20 ng/mL) for 24 h in the presence or absence of 1x10 5 normal BM-MSC (n=7) or AA BM-MSC (n=7).
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Extracellular matrix-degrading activities were determined as described elsewhere. 13 The MMP1 content was determined in supernatants by ELISA. Synovial membrane cells were stimulated with lipopolysaccharide 1 µg/mL in the presence or absence of 1x10 5 normal BM-MSC (n=7) or AA BM-MSC (n=7). After 48 h, culture supernatants were assayed for tumor necrosis factor-α by ELISA.
Results
Bone marrow mesenchymal stem/stromal cells from patients with aplastic anemia have a normal phenotype and differentiation potential
MSC cultures were successfully established and expanded from the BM of nine patients with AA and seven agematched healthy donors for further investigations. Table 1 presents the main biological and hematologic features of both groups. Established AA BM-MSC cultures were consistently devoid of contaminating hematopoietic cells, being negative for CD45, CD34, HLA-DR, CD19 and CD14 but expressed common MSC markers including CD90, CD73, CD105 and CD44 ( Figure 1 ). They had typical fibroblastoid morphology ( Figure 2 ). To further characterize MSC from AA patients, adipogenic and osteoblastic differentiation assays were performed at early MSC passages (p3-p5) ( Figure 2A ). 15, 31 The efficiency of osteoblastic and adipogenic differentiation was similar to BM-MSC in aplastic anemia haematologica | 2014; 99 (7) 1169 Figure 3A ). In the absence of MSC support, CD34
+ cells grew slightly slower ( Figure 3A ). There were no differences in apoptosis (~2-6%; Figure 3B ) or cycling status (~50%; Figure 3C ) of CB-CD34 + cells when co-cultured on BM-MSC from either normal subjects or from patients with AA, supporting a similar expansion of CB-CD34 + cells in any of the BM-MSC co-cultures ( Figure 3A) . In contrast, the slower growth of CD34 + cells maintained in the absence of MSC was accompanied by a higher apoptotic rate (~18% by day 12; Figure 3B ). We then analyzed the in vitro differentiation kinetics of CB-CD34 + cells by tracing the loss of the CD34 antigen, and found that CD34 + cells progressively disappeared within ~23 days on either normal or AA BM-MSC co-cultures ( Figure 3D ). Interestingly, in the absence of MSC support the differentiation of CD34 + cells was more pronounced. We next tested whether co-culture of CB-CD34 + cells with AA BM-MSC affects their hematopoietic progenitor cell and/or HSC function. We utilized in vitro clonogenic colony-forming unit (CFU) assays as a read-out for hematopoietic progenitor cell function. Equal numbers of CB-CD34 + cells that had been cultured for 2 or 4 days with normal or AA BM-MSC were plated in CFU assays and hematopoietic colonies were counted after 14 days (Figure 3E,F) . Scoring the CFU revealed that co-culture with AA BM-MSC did not influence either the clonogenic ability or the colony phenotype of CB-CD34 + cells. The CFU capacity of CD34 + cells that had not been previously cultured on MSC was slightly diminished (P>0.05).
Xenotransplantation assays into NSG mice were undertaken as an in vivo read-out for SCID-repopulating HSC function. CB-CD34 + cells (1x10 5 ) that had been cultured for 4 days with normal or AA BM-MSC were transplanted intratibia and mice were sacrificed 7 weeks later for chimerism analysis in multiple hematopoietic organs. Human multilineage reconstitution was determined by flow cytometry using anti-CD45, anti-HLA-ABC, anti-CD19, anti-CD33 and anti-CD34 ( Figure 4A ). CD34
+ cells co-cultured on either normal or AA BM-MSC displayed similar levels of engraftment (54% versus 61%; P>0.05. Figure 4B ). The migratory ability of CD34 + cells was assessed by analyzing the level of chimerism in the injected tibiae, contralateral tibiae, spleen, liver and peripheral haematologica | 2014; 99(7) blood ( Figure 4B ). Co-culture with either normal or AA BM-MSC did not influence the migratory capacity of CB-CD34 + hematopoietic stem and progenitor cells as demonstrated by the similar capacity to colonize other hematopoietic tissues in all the animals ( Figure 4B ). We next characterized the engraftment composition, and found a very similar multilineage composition in all tissues reconstituted with CB-CD34 + cells that had been co-cultured with either normal or AA BM-MSC ( Figure 4C ). The engraftment and multilineage reconstitution were very similar between CD34 + cells cultured alone or with MSC (Online Supplementary Figure S1 ). Taken together, these findings indicate that BM-MSC from AA patients support the in vitro homeostasis and the in vivo repopulating function of CB-CD34 + cells.
Bone marrow mesenchymal stem/stromal cells from patients with aplastic anemia maintain immunosuppressive and anti-inflammatory properties
Human BM-MSC display robust immunomodulatory and anti-inflammatory properties. Because an impaired immune response is suggested to be at the origin of the BM failure in AA we investigated whether the capacity of BM-MSC from AA patients to inactivate T-cell responses and to inhibit inflammatory responses is impaired. The addition of BM-MSC to mixed lymphocyte cultures of peripheral blood mononuclear cells from different donors significantly reduced the proliferative response ( Figure 5A ) and the production of Th1 cytokines (interferon-γ, interleukin-2 and tumor necrosis factor-α) by responder T cells ( Figure 5B ). The immunomodulatory activity of AA BM-MSC was comparable to that observed for normal BM-MSC ( Figure 5A,B) . Moreover, BM-MSC isolated from AA patients were very efficient at inhibiting the inflammatory response of resident cells of the synovial membrane in patients with active rheumatoid arthritis. BM-MSC isolated from AA patients or healthy subjects similarly inhibited the production of pro-inflammatory cytokines (tumor necrosis factor-α) and matrix-degrading enzymes (MMP1/MMP8/MMP13 type I collagenase and MMP2 gelatinase and type IV collagenase activities) by activated synovial membrane cells ( Figure 5C ). These data indicate that BM-MSC from AA patients fully retain their immunomodulatory capacities.
Discussion
AA is a rare, heterogeneous disorder in which the majority of cases are idiopathic, because the primary etiology is unknown. [1] [2] [3] In a subset of patients, a drug or infection has been implicated in the etiology, although it is unclear why only some individuals are susceptible. [4] [5] [6] [7] AA is generally considered as an immune-mediated BM failure syndrome BM-MSC in aplastic anemia haematologica | 2014; 99 (7) 1171 with defective HSC. 3, 32 Previous studies demonstrated the defective HSC as well as aberrant T-cell immunity in AA. 3, [33] [34] [35] Immunosuppressive therapy and allogeneic BM transplantation are the initial treatments of choice for newly diagnosed patients with severe AA. 1, 36 On the one hand, the good responses to immunosuppressive treatments such as antithymocyte globulin and cyclosporine A support the belief that pathological T-cell-mediated autoimmune responses are a cause of the BM failure in AA. 1, 34, 36 On the other hand, several studies have shown that co-transplantation of allogeneic BM-or CB-derived MSC and HSC enhances hematopoietic engraftment and also improves stromal function in patients with AA, [37] [38] [39] [40] suggesting a potential underlying role of the BM microenvironment in the pathogenesis of AA. In fact, AA patients have a hypocellular BM which is "physiologically" replaced by fatty BM, likely of mesenchymal origin, further supporting a potential contribution of the BM microenvironment to the pathogenesis of AA. 41 MSC have robust immunomodulatory and anti-inflammatory properties [11] [12] [13] and are an essential component of the BM hematopoietic microenvironment, which regulates the homeostasis of hematopoiesis through the production and secretion of cytokines and extracellular matrix molecules.
14 Importantly, the BM hematopoietic microenvironment has been shown to play a role in the pathogenesis of a variety of hematologic malignances including acute lymphoblastic 15 and myeloblastic leukemia, 16 multiple myelo-haematologica | 2014; 99(7) 17 lymphomas, 18 chronic myeloid leukemia 19 and myelodysplastic syndromes. 16, 20 We, therefore, hypothesized that BM-MSC may contribute, directly or indirectly, to the pathogenesis of AA.
There are limited studies with conflicting results on the properties of BM-MSC in AA patients. 8, [41] [42] [43] [44] [45] [46] [47] [48] These studies mainly claim that AA BM-MSC have aberrant morphology, impaired adipogenic and osteogenic potential, changes in gene expression, and a reduced ability to support hematopoiesis in vitro. However, to the best of our knowledge, no study so far has prospectively addressed in depth the ability of AA BM-MSC to maintain hematopoietic homeostasis and progenitor function in vitro, their in vivo repopulating function in xenotransplant models, or the immunosuppressive and anti-inflammatory properties on these cells. We comprehensively analyzed whether the functional and immunological properties of BM-MSC are impaired in AA patients and the potential contribution of these cells to the pathogenesis of the disease. We report that BM-MSC from AA patients have the same phenotype and differentiation potential as their counterparts from normal BM, support in vitro homeostasis and in vivo repopulating function of CD34 + hematopoietic stem and progenitor cells, and fully maintain immunosuppressive and anti-inflammatory properties. Our data indicate that BM-MSC from AA patients do not have impaired functional and immunological properties and retain the ability to support hematopoiesis, suggesting that they do not contribute to the pathogenesis of the disease. Interestingly, it has been reported that BM-MSC from AA patients overexpress membrane-bound interleukin-15 which may indirectly participate in the T-cell-mediated autoimmune attack of HSC in AA patients by recruiting T cells to the BM and stimulating them in situ. 46 Our data are in partial disagreement with those of other studies suggesting that AA BM-MSC are aberrant. 8, 41, 42, 44, 46, 48 From a methodological point of view, we assessed the features of AA BM-MSC beyond morphology, gene expression, differentiation potential and proliferation by analyzing the cells' ability to support hematopoiesis in vitro and in vivo and their immune properties. Biologically, all our patients, but one, were elderly patients while other studies focused on chil-BM-MSC in aplastic anemia haematologica | 2014; 99(7) dren/young adults with AA. 41, 42 Importantly, there are also several degrees of severity of AA. Our patients were diagnosed as having moderate-severe AA while other studies analyzed patients with very severe AA. In brief, further studies involving larger numbers of AA patients are necessary to unravel whether age at diagnosis and disease severity are key factors determining the homeostasis and function of the BM microenvironment in patients with "de novo" AA. 
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